Last reviewed · How we verify
S-892216
At a glance
| Generic name | S-892216 |
|---|---|
| Sponsor | Shionogi |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls (PHASE1)
- A Study of S-892216 in Participants With COVID-19 (PHASE2)
- Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants (PHASE1)
- A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-892216 CI brief — competitive landscape report
- S-892216 updates RSS · CI watch RSS
- Shionogi portfolio CI